Announced
Completed
Synopsis
Eli Lilly, a pharmaceutical company, completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, for $1.3bn. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment. We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease," Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite
Seller Team (12)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy